AC Immune (ACIU)
(Delayed Data from NSDQ)
$3.66 USD
-0.03 (-0.81%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $3.65 -0.01 (-0.27%) 4:54 PM ET
3-Hold of 5 3
D Value A Growth F Momentum D VGM
Price, Consensus and EPS Surprise
ACIU 3.66 -0.03(-0.81%)
Will ACIU be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ACIU based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACIU
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
ACIU: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
Other News for ACIU
Buy Rating Justified: AC Immune SA’s Strategic Advancements in Alzheimer’s Treatment and Strong Financial Position
Analyst Issues Buy Rating for AC Immune SA on Promising Alzheimer’s Treatment Prospects
AC Immune receives second milestone payment under Janssen agreement
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer?s Disease
AC Immune Advances in Alzheimer’s Trial, Secures Funding